Pre-earnings options volume in Aquestive Therapeutics is normal with calls leading puts 20:1. Implied volatility suggests the market is anticipating a move near 12.3%, or 42c, after results are released. Median move over the past eight quarters is 5.1%.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Biotech Alert: Searches spiking for these stocks today
- Aquestive Therapeutics receives FDA approval, market access for Libervant
- Largest borrow rate increases among liquid names
- Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
- Aquestive Therapeutics initiated with an Overweight at Piper Sandler